Genasys Inc. Reports Fiscal Fourth Quarter and Fiscal Year 2023 Financial Results
Genasys Protect Software Gaining MomentumSAN DIEGO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Genasys Inc. (NASDAQ: GNSS), the leader in Protective...
Read more
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society
REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to...
Read morePost Holdings Reports Avian Influenza at Third-Party Contracted Facilities and Updates Fiscal Year 2024 Adjusted EBITDA Outlook
ST. LOUIS, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Post Holdings, Inc. (NYSE:POST), a consumer packaged goods holding company, today provided...
Read moreMission Produce™ to Release Fiscal Fourth Quarter and Full Year 2023 Financial Results on Thursday, December 21, 2023
OXNARD, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Mission Produce, Inc. (Nasdaq: AVO) (“Mission” or the “Company”), a world leader...
Read moreHashiCorp Announces Third Quarter of Fiscal Year 2024 Financial Results
Third quarter revenue totaled $146.1 million, representing an increase of 17% year-over-year.Trailing four quarter average Net Dollar Retention Rate was...
Read moreThe Providence Group Joins Again with St. Jude Children’s Research Hospital to Build the Atlanta 2024 St. Jude Dream Home
ATLANTA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- The Providence Group, a premier developer and homebuilder of award-winning neighborhoods throughout Atlanta,...
Read moreAAR to announce second quarter fiscal year 2024 results on December 21, 2023
Wood Dale, Illinois, Dec. 07, 2023 (GLOBE NEWSWIRE) -- AAR CORP. (NYSE: AIR), a leading provider of aviation services to...
Read moreAvid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023
-- Recorded Second Quarter Revenue of $25.4 Million -- -- Signed $35 Million in Net New Business Orders Resulting in...
Read moreAligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...
Read moreCassava Sciences Appoints Three New Members to its Board of Directors
Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the...
Read moreADVERTISEMENTS
Shortcodes Ultimate
ADVERTISEMENTS
